Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 7/20 | 0.46 |
| ▸ | METAP1 | P53582 | 4/20 | 0.46 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7968560 | 0.99 | CNR1 (0.50) | CNR1ALDH1A1HPGDHTTIDO1 | |
| SCHEMBL10310231 | 0.88 | CNR1 (0.56) | CNR1ALDH1A1HPGDHTTIDO1 | |
| SCHEMBL9843530 | 0.85 | HTT (0.50) | ALDH1A1HPGDHTTIDO1MAPK1 | |
| SCHEMBL17198925 | 0.82 | CNR1 (0.42) | CNR1ALDH1A1MAPK1 | |
| SCHEMBL14868788 | 0.82 | TAAR1 (0.49) | CNR1HTTIDO1PLAAT3PLAAT5 | |
| SCHEMBL8441620 | 0.78 | IDO1 (0.60) | CNR1IDO1KMT2A | |
| SCHEMBL20258635 | 0.78 | MTNR1A (0.62) | HPGD | |
| SCHEMBL21562513 | 0.78 | MTNR1A (0.50) | KMT2A | |
| Hydrochloric Acid SCHEMBL19371410 | 0.77 | IDO1 (0.58) | CNR1IDO1KMT2A | |
| SCHEMBL14868703 | 0.77 | SMN1; SMN2 (0.52) | CNR1ALDH1A1HPGDHTTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| WO-2001010849-A2 | SUBSTITUTED ARYLALKYLAMINO-1,3,5-TRIAZINES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | CNR1 4511/4885ALDH1A1 1471/4885HPGD 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.